Department of Periodontics, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, India.
Molecular Biology Laboratory, Centre for Cellular and Molecular Research, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, 600077, India.
Odontology. 2024 Oct;112(4):1326-1334. doi: 10.1007/s10266-024-00929-x. Epub 2024 Apr 4.
Abnormal expression of SEC14L2 has been implicated in many human cancers. However, the role of SEC14L2 in oral squamous cell carcinoma (OSCC) remains unclear. Therefore, this study aimed to evaluate the expression and prognostic roles of SEC14L2 in OSCC. OSCC tumors and adjacent non-tumors were collected from OSCC patients and used for SEC14L2 mRNA expression by quantitative reverse transcription PCR (RT-qPCR). Additionally, the expression of SEC14L2 was further analyzed using The Cancer Genome Atlas-Head Neck Squamous Cell Carcinoma (TCGA-HNSCC) dataset to identify its relationship with HNSCC clinical characteristics. The Kaplan-Meier plot was used to assess survival rates, and the Tumor Immune Estimation Resource (TIMER) database was used to examine the correlation between SEC14L2 expression and tumor immune cell infiltration. In silico tools also looked at SEC14L2 involvement in cancer pathways through its protein network. The mRNA and protein levels of SEC14L2 are notably higher in both OSCC and HNSCC tissues compared to adjacent normal tissues. Upregulation of SEC14L2 was associated with advanced tumor stages, grades, metastasis, HPV-negative, and TP53 mutations in cancer patients. In addition, the high expression of SEC14L2 was negatively correlated with the poor survival of cancer patients and the infiltration of diverse immune cells in cancer patients. According to the findings of this investigation, SEC14L2 is significantly elevated in OSCC/HNSCC patients and associated with a worse prognosis. More investigation and clinical studies are required to completely understand the therapeutic potential of SEC14L2 in HNSCC and convert these findings into better patient outcomes.
SEC14L2 的异常表达与许多人类癌症有关。然而，SEC14L2 在口腔鳞状细胞癌（OSCC）中的作用尚不清楚。因此，本研究旨在评估 SEC14L2 在 OSCC 中的表达和预后作用。从 OSCC 患者中收集 OSCC 肿瘤和相邻非肿瘤组织，通过定量逆转录 PCR（RT-qPCR）检测 SEC14L2 mRNA 表达。此外，还使用癌症基因组图谱-头颈部鳞状细胞癌（TCGA-HNSCC）数据集进一步分析 SEC14L2 的表达，以确定其与 HNSCC 临床特征的关系。Kaplan-Meier 图用于评估生存率，肿瘤免疫估计资源（TIMER）数据库用于检查 SEC14L2 表达与肿瘤免疫细胞浸润的相关性。通过其蛋白质网络，计算工具还研究了 SEC14L2 参与癌症途径的情况。与相邻正常组织相比，OSCC 和 HNSCC 组织中的 SEC14L2 mRNA 和蛋白水平明显升高。SEC14L2 的上调与癌症患者的晚期肿瘤分期、分级、转移、HPV 阴性和 TP53 突变有关。此外，SEC14L2 的高表达与癌症患者的不良生存和癌症患者不同免疫细胞的浸润呈负相关。根据本研究的结果，SEC14L2 在 OSCC/HNSCC 患者中显著升高，并与预后不良相关。需要进一步的研究和临床研究来充分了解 SEC14L2 在 HNSCC 中的治疗潜力，并将这些发现转化为更好的患者结局。
